Qiagen schedules shareholder vote on new CEO appointment

QIAGEN N.V., a Netherlands-based company specializing in sample-to-insight solutions for molecular information extraction and analysis from biological samples, has announced an upcoming Extraordinary General Meeting of Shareholders scheduled for November 6, 2026. At the meeting, shareholders will have the opportunity to vote on the appointment of Jonathan M. Pratt as a member of the company's Management Board.

Pratt assumed his role as Chief Executive Officer on September 1, 2026, and would be joined by Roland Sackers, the current Chief Financial Officer, upon approval.

Furthermore, shareholders will also cast their votes on the discharge of Thierry Bernard, who served as Managing Board member until his resignation on September 1, 2026. All relevant meeting materials, including the agenda and explanatory notes, will be made accessible to shareholders in compliance with applicable regulations and on QIAGEN's Investor Relations website.

QIAGEN, headquartered in Venlo, Netherlands, caters to over 500,000 customers globally in the life sciences and molecular diagnostics sectors. As of June 30, 2026, the company employed approximately 5,500 individuals across more than 35 locations.